67 FR 101 pg. 36577 - Availability for Non-Exclusive, or Partially Exclusive Licensing of U.S. Patent Application Concerning Antibodies Against Type A Botulinum Neurotoxin
Type: NOTICEVolume: 67Number: 101Page: 36577
FR document: [FR Doc. 02-13045 Filed 5-23-02; 8:45 am]
Agency: Defense Department
Sub Agency: Department of the Army
Official PDF Version: PDF Version
DEPARTMENT OF DEFENSE
Department of the Army
Availability for Non-Exclusive, or Partially Exclusive Licensing of U.S. Patent Application Concerning Antibodies Against Type A Botulinum Neurotoxin
AGENCY:
Department of the Army, DOD
ACTION:
Notice.
SUMMARY:
In accordance with 37 CFR 404.6 and 404.7, announcement is made of the availability for licensing of U.S. Patent Application No. 09/465,276 entitled "Antibodies Against Type A Botulinum Neurotoxin," filed December 16, 1999. The United States Government, as represented by the Secretary of the Army has rights in this invention.
ADDRESSES:
Commander, U.S. army Medical Research and Materiel Command, ATTN: Command Judge Advocate, MCMR-JA, 504 Scott Street, Fort Detrick Frederick, MD 21702-5012.
FOR FURTHER INFORMATION CONTACT:
For patent issues, Ms. Elizabeth Arwine, Patent Attorney, (301) 619-7808. For licensing issues, Dr. Paul Mele, Office of Research Technology Assessment, (301) 619-6664, both at telefax (301) 619-5034.
SUPPLEMENTARY INFORMATION:
Antibodies for binding epitopes of BoNT/A and hybridomas which produce such antibodies are described. The antibodies of the present invention can be used in a method for detecting BoNT/A in a sample and/or in a method for purifying BoNT/A from an impure solution. In addition, the antibodies can to be used for passive immunization against BoNT/A intoxication or as intoxication therapy. Another aspect of the invention is a kit for detecting BoNT/A in a sample.
Luz D. Ortiz,
Army Federal Register Liaison Officer.
[FR Doc. 02-13045 Filed 5-23-02; 8:45 am]
BILLING CODE 3710-08-M